Full history for every metric is available with a Kvantra account
Key financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 3,118 | 3,376 | 3,589 | 3,675 | 3,980 | 4,070 | 3,991 | 4,132 |
| Operating profit | €m | 561 | 478 | ||||||
| Net profit | €m | 404 | 601 | 452 | 358 | 432 | 398 | 462 | 513 |
| EPS reported | € | 3.34 | 3.90 | ||||||
| Operating cashflow per share | € | 6.68 | 7.71 | ||||||
| Capex per share | € | 2.84 | 2.74 | ||||||
| FCF per share | € | 3.84 | 4.97 | ||||||
| Free cash flow | €m | 453 | 586 | ||||||
| Net debt | €m | -259 | -391 | ||||||
| Book value equity | €m | 4,102 | 4,297 | ||||||
| Book value per share | € | 34.47 | 36.30 | ||||||
| Number of shares | m | 119.01 | 118.38 | ||||||
| DPS (TTM paid) | € | 0.98 | 0.98 |
Financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 33.02 | - | ||||||
| P/B LTM | x | 3.17 | 2.11 | ||||||
| P/S LTM | x | 3.20 | 2.27 | ||||||
| P/FCF LTM | x | 28.72 | 15.47 | ||||||
| EV/EBITDA LTM | x | 12.91 | 9.45 | ||||||
| EV/Sales LTM | x | 3.17 | 2.17 | ||||||
| Earnings Yield LTM | % | 3.03% | 5.12% | ||||||
| FCF Yield | % | 3.48% | 6.47% | ||||||
| Quality | |||||||||
| ROE | % | 9.69% | 11.01% | ||||||
| ROIC | % | 9.13% | 7.59% | ||||||
| Operating margin | % | 13.79% | 11.99% | ||||||
| Gross margin | % | 52.63% | 52.04% | ||||||
| FCF/Sales | % | 11.13% | 14.67% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | -8.24% | +23.03% | ||||||
| Sales Growth YoY | % | +2.26% | -3.18% | ||||||
| Net Income Growth YoY | % | -8.03% | +22.36% | ||||||
| FCF Growth | % | +40.90% | +33.25% | ||||||
| Operating Profit Growth | % | -4.69% | -6.01% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.82% | 1.28% | ||||||
| Dividend Growth | % | +8.89% | +8.89% | ||||||
| Payout Ratio | % | 26.69% | 26.69% | ||||||
| FCF/Debt | x | 0.98 | 1.39 | ||||||
| Net Debt/EBITDA | x | -0.11 | -0.26 | ||||||
| EBIT/Net interest | x | 35.52 | 57.63 | ||||||
| Net debt/market cap | % | -1.99% | -4.31% | ||||||
| Net debt/Equity | x | -0.06 | -0.09 | ||||||
| Gross debt/equity | x | 0.11 | 0.10 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
bioMérieux S.A. is a global entity operating across the Americas, Europe, the Middle East, Africa, and the Asia Pacific, specializing in the development and production of in vitro diagnostic solutions. The company's sophisticated systems utilize biological samples to identify infectious diseases, cardiovascular conditions, and various forms of cancer. Additionally, bioMérieux provides essential microbiological testing services for the manufacturing sectors, primarily serving the food, pharmaceutical, cosmetics, and veterinary industries. Its client base includes clinical and hospital laboratories, medical practitioners, blood banks, and industrial quality control facilities. Founded in 1963, originally under the name B-D Mérieux, bioMérieux S.A. maintains its headquarters in Marcy l'Etoile, France, and functions as a subsidiary of Institut Mérieux SA.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Based on consensus from external analysts. Not Kvantra's opinion.
bioMérieux S.A. is a global entity operating across the Americas, Europe, the Middle East, Africa, and the Asia Pacific, specializing in the development and production of in vitro diagnostic solutions. The company's sophisticated systems utilize biological samples to identify infectious diseases, cardiovascular conditions, and various forms of cancer. Additionally, bioMérieux provides essential microbiological testing services for the manufacturing sectors, primarily serving the food, pharmaceutical, cosmetics, and veterinary industries. Its client base includes clinical and hospital laboratories, medical practitioners, blood banks, and industrial quality control facilities. Founded in 1963, originally under the name B-D Mérieux, bioMérieux S.A. maintains its headquarters in Marcy l'Etoile, France, and functions as a subsidiary of Institut Mérieux SA.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free